Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes

Journal of Urology

Volumn 177, Issue 2, 2007, Pages 540-545

  Cookson, Michael S ^a   Aus, Gunnar ^a   Burnett, Arthur L ^a   Canby Hagino, Edith D ^a   D'Amico, Anthony V ^a   Dmochowski, Roger R ^a   Eton, David T ^a   Forman, Jeffrey D ^a   Goldenberg, S Larry ^a   Hernandez, Javier ^a   Higano, Celestia S ^a   Kraus, Stephen R ^a   Moul, Judd W ^a   Tangen, Catherine ^a   Thrasher, J Brantley ^a   Thompson, Ian ^a  

^a NONE

Author keywords

practice guidelines; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ALGORITHM; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CHEMICAL ANALYSIS; CLINICAL PROTOCOL; DATA BASE; HUMAN; MALE; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; STANDARD; TREATMENT OUTCOME;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 33846002787     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.10.097     Document Type: Article

References (20)

1. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
2. Trapasso J.G., deKernion J.B., Smith R.B., and Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152 (1994) 1821
3. Zincke H., Oesterling J.E., Blute M.L., Bergstralh E.J., Myers R.P., and Barrett D.M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850
4. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035
5. Lange P.H., Ercole C.J., Lightner D.J., Fraley E.E., and Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141 (1989) 873
6. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 163 (2000) 1632
7. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M., and Zincle H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001) 1146
8. Vicini F.A., Kestin L., and Martinez A. Biochemical outcomes of treatment for prostate cancer. JAMA 284 (2000) 2869
9. Critz F.A. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 167 (2002) 1310
10. Gretzer M.B., Trock B.J., Han M., and Walsh P.C. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 168 (2002) 1419
11. Horwitz E.M., Thames H.D., Kuban D.A., Levy L.B., Kupelian P.A., Martinez A.A., et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173 (2005) 797
12. Kuban D., Thames H., Levy L., Horwitz E., Kupelian P., Martinez A., et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?. Int J Radiat Oncol Biol Phys 61 (2005) 409
13. Coen J.J., Chung C.S., Shipley W.U., and Zietman A.L. Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. Int J Radiat Oncol Biol Phys 57 (2003) 621
14. Middleton R.G., Thompson I.M., Austenfeld M.S., Cooner W.H., Correa R.J., Gibbons R.P., et al., The American Urological Association. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. J Urol 154 (1995) 2144
15. Kattan M.W., Fearn P.A., Leibel S., and Potters L. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 48 (2000) 1469
16. D'Amico A.V., Whittington R., Malkowicz S.B., Cote K., Loffredo M., Schultz D., et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95 (2002) 281
17. Stokes S.H. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound- guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 47 (2000) 129
18. Kupelian P.A., Potters L., Khuntia D., Ciezki J.P., Reddy C.A., Reuther A.M., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25
19. Diblasio C.J., and Kattan M.W. Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. Urology, suppl. 62 (2003) 9
20. Moul J.W. Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol 21 (2003) 292